About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 958025, 11 pages
http://dx.doi.org/10.1155/2013/958025
Research Article

Antitumor Effect of Periplocin in TRAIL-Resistant Human Hepatocellular Carcinoma Cells through Downregulation of IAPs

Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan

Received 23 August 2012; Revised 15 November 2012; Accepted 15 November 2012

Academic Editor: Andreas Sandner-Kiesling

Copyright © 2013 Chieh-Fang Cheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplemental Figure 1: The ROS production in HA22T/VGH cells was regulated by periplocin and/or TRAIL treatment. HA22T/VGH cells were treated with periplocin and/or TRAIL for 1 hr with or without 1-hr pretreatment of NAC (30 mM). DCHF-DA was added into each sample for 30 min, and the DCF fluorescence intensity in cells was detected by FACS analysis.

Supplemental Figure 2: The dose-dependent effect of periplocin on apoptosis-related proteins. (A) The expression levels of Bax, Bad, Mcl-1, apaf-1, and caspase 9 in HA22T/VGH in response to different doses of periplocin treatments with or without TRAIL treatment were examined by Western blot. (B) The expression levels of Bcl-2, cIAP-1, cIAP-2, XIAP, and survivin in HA22T/VGH in response to different doses of periplocin treatments with or without TRAIL treatment were examined by Western blot.

  1. Supplementary Figures